Street Calls of the Week
Investing.com - H.C. Wainwright has reiterated its Buy rating and $4.00 price target on Boundless Bio Inc. (NASDAQ:BOLD), representing a significant upside from the current price of $1.41, following positive preclinical data presented at the AACR-NCI-EORTC conference. According to InvestingPro data, analyst targets range from $3.00 to $4.00, with two analysts recently revising earnings estimates upward.
The research firm highlighted robust anti-tumor activity from the combination of BBI-825, an RNR inhibitor, and BBI-355, a CHK1 inhibitor, in FGFR2- and MYC-amplified gastric models. The drug combination also produced durable tumor regressions in MYC-amplified small cell lung cancer models with minimal bone marrow suppression.
These preclinical results align with the intermittent dosing strategy being implemented in the company’s ongoing Phase 1/2 POTENTIATE trial. Boundless Bio has indicated it expects to achieve proof-of-concept within its current cash runway, which extends through the first half of 2028.
H.C. Wainwright noted that a critical threshold for the program will be maintaining no Grade 3 or higher cytopenias at active doses. Previous CHK1 inhibitor programs were halted when neutropenia and thrombocytopenia prevented therapeutic exposure.
The firm believes demonstrating that the selective RNR inhibitor and intermittent CHK1 inhibitor schedule can separate efficacy from hematologic toxicity would represent the program’s first major clinical risk mitigation.
In other recent news, Boundless Bio has announced the opening of enrollment for the BBI-355 and BBI-825 combination arm of its Phase 1/2 POTENTIATE trial. This trial aims to address hematologic toxicity and avoid CYP induction with a revised dosing regimen. Meanwhile, H.C. Wainwright has adjusted its price target for Boundless Bio, lowering it to $4.00 from the previous $5.00, while maintaining a Buy rating on the company. This decision follows the recent developments in the company’s clinical trials. The firm’s analysis reflects its continued support for Boundless Bio’s strategy despite the revised price target. These updates provide investors with the latest insights into the company’s ongoing projects and analyst perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.